Evidence map›Paper›PMID 37041522›Full record

Observational studyBMC cancer2023

Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study.

Sofie Olsson Hau, Caroline Williamsson, Bodil Andersson, Jakob Eberhard, Karin Jirström

Registry-linked trialOpen access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03724994 (Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03724994 completednot on this map

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

Typeobservational_patient_registrySponsorLund UniversityRan2018 to 2024Enrolled201ConditionsPeriampullary Adenocarcinoma, Periampullary Cancer, Pancreatic CancerArmsGemcitabine
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. [Sex differences in pancreatic cancer].Chirurgie (Heidelberg, Germany) · 2024
    Review
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sofie Olsson HauDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, SE-221 85, Lund, Sweden. sofie.olsson_hau@med.lu.se.
Caroline WilliamssonDivision of Surgery, Department of Clinical Sciences, Lund University, Lund, Sweden.
Bodil AnderssonDivision of Surgery, Department of Clinical Sciences, Lund University, Lund, Sweden.
Jakob EberhardDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, SE-221 85, Lund, Sweden.
Karin JirströmDivision of Oncology and Therapeutic Pathology, Department of Clinical Sciences, Lund University, SE-221 85, Lund, Sweden.
Lund University · SE

Funding

Cancerfonden CAN2018/418, 21 1596 PjVetenskapsrådet 2015-03598, 2018-02441
6 · The paper itself

Abstract

backgroundPeriampullary cancer is a term for cancers arising in or in close proximity to the pancreas. Pancreatic cancer is the 3

methodsThe study cohort consists of the first 100 patients, 49 women and 51 men, enrolled in the Chemotherapy, Host Response and Molecular dynamics in Periampullary cancer (CHAMP) study, an ongoing study of patients undergoing neoadjuvant, adjuvant or first-line palliative chemotherapy treatment. Twenty-five patients had surgery with curative intent and subsequent adjuvant treatment, and 75 patients were treated with palliative chemotherapy. Data regarding health-related quality of life (HRQoL, EORTC-QLQ-C30) at baseline, demographic and clinicopathological factors were examined and stratification by treatment intention according to sex. Overall survival (OS) was calculated through Kaplan-Meier analysis.

resultsThere was a statistically significant difference between male and female patients treated with curative intent, with fewer women having undergone surgery (18 vs 7, p = 0.017), also after adjustment for age, tumor location and performance status. No statistical differences were found between the sexes regarding age, comorbidities, or clinicopathological factors. Before start of chemotherapy treatment, health-related quality of life (HRQoL) was lower in female than in male patients. However, HRQoL was not associated with performance status in female patients, whereas in male patients several HRQoL indicators were significantly positively associated with poorer performance status at baseline.

conclusionsThis study shows no clear differences between the sexes regarding biological factors concluding that gender bias might be responsible for the discrepancy between men and women being offered curative surgery. The observed difference between women and men regarding the association between HRQoL and performance status is unprecedented. Altogether these findings underline the importance of taking gender into consideration when assessing eligibility for curative surgery in order to improve biological outcome and decrease suffering in both sexes.

trial registrationNCT03724994.

Indexed as

NeoplasmsQuality of LifeFemaleHumansIntentionMaleProspective StudiesSex FactorsSexismChemotherapyGenderPancreatic cancerPerformance statusPeriampullary cancerQuality of lifeSexTreatment intention

Identifiers

PMID37041522
PMCPMC10088105
OpenAlexW4364377275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.